为您找到相关结果约500个

你是不是要搜索 期刊Atezolizumab Plus Chemotherapy for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer: Results From the Randomized Phase III IMpower132 Trial 点击跳转

Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the RandomizedPhase 3 IMpower132 Trial

Results from the IMpower132 China cohort: Atezolizumab plus platinum-based chemotherapy in advanced non-smallcell lung cancer

First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectivenessanalysis from China

Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of MetastaticNon-Squamous Non-Small Cell Lung Cancer

Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-CellLung Cancer A Phase 3 Randomized Clinical Trial

Final efficacy results from IMpower132: First-line atezolizumab plus chemotherapy in patients with stageIV non-squamous NSCLC

Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phaseIII CheckMate 227 Part 2 trial

Bevacizumab/PD-1 inhibitor plus chemotherapy as first-line treatment of advanced non-squamous non-small-celllung cancer

Atezolizumab Monotherapy or Plus Chemotherapy in First-Line Treatment for Advanced Non-Small Cell LungCancer Patients: A Meta-Analysis

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluatingsecond-line atezolizumab versus docetaxel

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapyalone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): amulticentre, randomised, open-label, phase 3 tria

Phase III study of tislelizumab plus chemotherapy vs chemotherapy alone as first-line (1L) treatmentfor advanced squamous non-small cell lung cancer (sq NSCLC).

Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-SmallCell Lung Cancer

First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectivenessanalysis from China

为您找到相关结果约500个

共500条页码: 1/34页15条/页